oxandrolone has been researched along with Turner Syndrome in 101 studies
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.
Turner Syndrome: A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The UK Turner syndrome (TS) study examined the effect on final height of oxandrolone 0." | 9.41 | Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial. ( Betts, P; Casey, S; Cole, TJ; Donaldson, MDC; Dunger, DB; Gault, EJ; Hindmarsh, PC, 2021) |
| "To evaluate karyotype-specific ear and hearing problems in young-adult patients with Turner syndrome (TS) and assess the effects of previous treatment with oxandrolone (Ox)." | 9.19 | Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment. ( Admiraal, RJ; de Muinck Keizer-Schrama, SM; Freriks, K; Hermus, AR; Huygen, PL; Kunst, HP; Menke, LA; Otten, BJ; Pennings, RJ; Sas, TC; Smeets, DF; Timmers, HJ; Topsakal, V; van Alfen-van der Velden, JA; Verver, EJ; Wit, JM, 2014) |
| "The weak androgen oxandrolone (Ox) may increase height but may also affect glucose metabolism in girls with Turner syndrome (TS)." | 9.15 | Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. ( de Muinck Keizer-Schrama, SM; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2011) |
| "Oxandrolone (Ox) increases height gain but may also cause voice deepening in growth hormone (GH)-treated girls with Turner syndrome (TS)." | 9.15 | The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome. ( Boersma, B; de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Menke, LA; Otten, BJ; Sas, TC; van Koningsbrugge, SH; Wit, JM; Zandwijken, GR, 2011) |
| "The weak androgen oxandrolone (Ox) increases height gain in growth-hormone (GH) treated girls with Turner syndrome (TS), but may also give rise to virilizing side effects." | 9.14 | The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome. ( Cohen-Kettenis, PT; de Muinck Keizer-Schrama, SM; Kreukels, BP; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Visser, M; Wit, JM; Zandwijken, GR, 2010) |
| "The objective of this study was to find out whether moderate doses of growth hormone (GH) in combination with oxandrolone (Ox) and late initiation of puberty could improve adult height even in relatively old patients with Ullrich-Turner syndrome (UTS)." | 9.10 | Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. ( Keller, E; Landy, H; Stahnke, N, 2002) |
| "The aims of this comparative multicenter study of 67 girls with Turner syndrome (TS) on three different therapeutical regimens were, first, to evaluate the effect of either recombinant human growth hormone (GH) alone or in combination with the anabolic steroid oxandrolone (Oxa) on height velocity and on Turner-specific bone age (BA'TS) and, second, to estimate the gain in final height taking the age at the onset of treatment into account." | 9.08 | Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome? ( Joss, EE; Mullis, PE; Partsch, CJ; Sippell, WG; Werder, EA, 1997) |
| "Final stature in girls with Turner syndrome treated with combination of low dose oestrogen and oxandrolone." | 9.08 | Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. ( Bareille, P; Massarano, AA; Stanhope, R, 1997) |
| "Seventy girls with Turner syndrome, verified by karyotype, were randomly assigned to observation or treatment with human growth hormone (hGH), oxandrolone, or a combination of hGH plus oxandrolone for a period of 12 to 24 months, to assess the effect of treatment on growth velocity and adult height." | 9.07 | Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. ( Attie, KM; Brasel, JA; Burstein, S; Cara, JF; Chernausek, S; Frane, J; Gotlin, RW; Kuntze, J; Lippe, BM; Rosenfeld, RG, 1992) |
| "In order to examine whether the anabolic steroid oxandrolone has any long-term effect on height in Turner syndrome, the short- and long-term effects were studied in a group of 35 individuals with the syndrome." | 9.06 | Oxandrolone increases final height in Turner syndrome. ( Crock, P; Werther, GA; Wettenhall, HN, 1990) |
| "Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone." | 9.06 | Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. ( Brasel, JA; Burstein, S; Chernausek, S; Compton, P; Frane, J; Gotlin, RW; Hintz, RL; Johanson, AJ; Rosenfeld, RG; Sherman, B, 1988) |
| "To assess the effects of oxandrolone on growth hormone-treated girls aged up to 18 years with Turner syndrome." | 9.01 | Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome. ( Adi, YA; AlFaleh, K; Alkofide, H; Amer, YS; Mohamed, S, 2019) |
| "There has been no consensus regarding the efficacy and safety of oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS), the optimal age of starting this treatment, or the optimal dose." | 8.90 | Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. ( Bardsley, MZ; de Muinck Keizer-Schrama, SM; Donaldson, MD; Freriks, K; Gault, EJ; Menke, LA; Otten, BJ; Perry, RJ; Ross, JL; Sas, TC; Timmers, H; Wit, JM, 2014) |
| "Combined treatment with growth hormone and oxandrolone results in a significant increase of insulin secretion and increased insulin resistance." | 7.73 | [Carbohydrate metabolism in patients with Turner syndrome. The effect of therapy with growth hormone, oxandrolone and a combination of both]. ( Starzyk, J, 2005) |
| "In 18 girls with Turner syndrome, glucose tolerance was studied before treatment and after 6 and 24 months of growth-promoting treatment with recombinant human growth hormone (24 IU/m(2)/week; 8 mg/m(2)/week) and oxandrolone (0." | 7.70 | Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome. A longitudinal study. ( Joss, EE; Mullis, PE; Tönz, O; Zurbrügg, RP, 2000) |
| "To evaluate the effects of growth-promoting therapy on carbohydrate metabolism in girls with Turner syndrome, we determined glucose and insulin concentrations during oral glucose tolerance tests (OGTTs) at baseline and after 5 days, 2 months, and 12 months of treatment with growth hormone (GH), oxandrolone, or a combination of GH and oxandrolone, or after the same intervals with no therapy." | 7.67 | Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. ( Frane, JW; Hintz, RL; Johanson, AJ; Rosenfeld, RG; Sherman, B; Wilson, DM, 1988) |
| " The increase in BMI and waist circumference SDS was comparable between the dosage groups." | 6.75 | The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome. ( de Muinck Keizer-Schrama, SM; de Ridder, MA; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2010) |
| "In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0." | 6.75 | Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. ( de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Delemarre-van de Waal, HA; Gevers, EF; Hokken-Koelega, AC; Jansen, M; Menke, LA; Odink, RJ; Otten, BJ; Reeser, HM; Sas, TC; Stokvis-Brantsma, WH; van Buuren, S; van Trotsenburg, AS; Waelkens, JJ; Westerlaken, C; Wit, JM; Zandwijken, GR, 2010) |
| " Conventional GH doses are effective in increasing growth velocity in UTS, especially, when combined with Ox." | 6.68 | Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995) |
| "The UK Turner syndrome (TS) study examined the effect on final height of oxandrolone 0." | 5.41 | Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial. ( Betts, P; Casey, S; Cole, TJ; Donaldson, MDC; Dunger, DB; Gault, EJ; Hindmarsh, PC, 2021) |
| "Mild virilization persists in only a small minority of patients." | 5.39 | Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome. ( de Muinck Keizer-Schrama, SM; Dejonckere, PH; den Heijer, M; Freriks, K; Gotthardt, M; Hermus, AR; Menke, LA; Netea-Maier, RT; Otten, BJ; Sas, TC; Timmers, HJ; Traas, MA; van Alfen-van der Velden, JA; Wit, JM; Zandwijken, GR, 2013) |
| "A UK study showed final height in Turner syndrome (TS) girls receiving growth hormone is affected by age at pubertal induction and oxandrolone (Ox)." | 5.19 | Effect of oxandrolone and timing of oral ethinylestradiol initiation on pubertal progression, height velocity and bone maturation in the UK Turner study. ( Donaldson, MD; Dunger, DB; Gault, EJ; Paterson, WF; Perry, RJ, 2014) |
| "To evaluate karyotype-specific ear and hearing problems in young-adult patients with Turner syndrome (TS) and assess the effects of previous treatment with oxandrolone (Ox)." | 5.19 | Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment. ( Admiraal, RJ; de Muinck Keizer-Schrama, SM; Freriks, K; Hermus, AR; Huygen, PL; Kunst, HP; Menke, LA; Otten, BJ; Pennings, RJ; Sas, TC; Smeets, DF; Timmers, HJ; Topsakal, V; van Alfen-van der Velden, JA; Verver, EJ; Wit, JM, 2014) |
| "The weak androgen oxandrolone (Ox) may increase height but may also affect glucose metabolism in girls with Turner syndrome (TS)." | 5.15 | Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. ( de Muinck Keizer-Schrama, SM; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2011) |
| "Oxandrolone (Ox) increases height gain but may also cause voice deepening in growth hormone (GH)-treated girls with Turner syndrome (TS)." | 5.15 | The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome. ( Boersma, B; de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Menke, LA; Otten, BJ; Sas, TC; van Koningsbrugge, SH; Wit, JM; Zandwijken, GR, 2011) |
| "The weak androgen oxandrolone (Ox) increases height gain in growth-hormone (GH) treated girls with Turner syndrome (TS), but may also give rise to virilizing side effects." | 5.14 | The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome. ( Cohen-Kettenis, PT; de Muinck Keizer-Schrama, SM; Kreukels, BP; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Visser, M; Wit, JM; Zandwijken, GR, 2010) |
| "The objective of this study was to find out whether moderate doses of growth hormone (GH) in combination with oxandrolone (Ox) and late initiation of puberty could improve adult height even in relatively old patients with Ullrich-Turner syndrome (UTS)." | 5.10 | Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. ( Keller, E; Landy, H; Stahnke, N, 2002) |
| "Final stature in girls with Turner syndrome treated with combination of low dose oestrogen and oxandrolone." | 5.08 | Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. ( Bareille, P; Massarano, AA; Stanhope, R, 1997) |
| "The aims of this comparative multicenter study of 67 girls with Turner syndrome (TS) on three different therapeutical regimens were, first, to evaluate the effect of either recombinant human growth hormone (GH) alone or in combination with the anabolic steroid oxandrolone (Oxa) on height velocity and on Turner-specific bone age (BA'TS) and, second, to estimate the gain in final height taking the age at the onset of treatment into account." | 5.08 | Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome? ( Joss, EE; Mullis, PE; Partsch, CJ; Sippell, WG; Werder, EA, 1997) |
| "Seventy girls with Turner syndrome, verified by karyotype, were randomly assigned to observation or treatment with human growth hormone (hGH), oxandrolone, or a combination of hGH plus oxandrolone for a period of 12 to 24 months, to assess the effect of treatment on growth velocity and adult height." | 5.07 | Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. ( Attie, KM; Brasel, JA; Burstein, S; Cara, JF; Chernausek, S; Frane, J; Gotlin, RW; Kuntze, J; Lippe, BM; Rosenfeld, RG, 1992) |
| "Beginning in 1983, 71 girls with Turner syndrome were enrolled in a prospective, randomized study of human growth hormone (hGH), alone and in combination with oxandrolone; 4-5 patient-year data are currently available on 66 subjects." | 5.06 | Non-conventional growth hormone therapy in Turner syndrome: the United States experience. ( Rosenfeld, RG, 1990) |
| "In 1983, a multicenter, collaborative, prospective study was begun to investigate the efficacy of human growth hormone (hGH), alone and in combination with oxandrolone, in girls with Turner syndrome." | 5.06 | Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results. ( Rosenfeld, RG, 1989) |
| "Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone." | 5.06 | Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome. ( Brasel, JA; Burstein, S; Chernausek, S; Compton, P; Frane, J; Gotlin, RW; Hintz, RL; Johanson, AJ; Rosenfeld, RG; Sherman, B, 1988) |
| "In order to examine whether the anabolic steroid oxandrolone has any long-term effect on height in Turner syndrome, the short- and long-term effects were studied in a group of 35 individuals with the syndrome." | 5.06 | Oxandrolone increases final height in Turner syndrome. ( Crock, P; Werther, GA; Wettenhall, HN, 1990) |
| "The linear growth effects of oxandrolone, human growth hormone, and Ox + hGH were compared in six girls, age 11 to 15 years, with X chromosome abnormalities (three with X,O karyotype, three with Turner syndrome variants)." | 5.05 | Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. ( Blackston, D; Goldsmith, M; Kutner, M; Rudman, D, 1980) |
| "To assess the effects of oxandrolone on growth hormone-treated girls aged up to 18 years with Turner syndrome." | 5.01 | Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome. ( Adi, YA; AlFaleh, K; Alkofide, H; Amer, YS; Mohamed, S, 2019) |
| " The addition of oxandrolone to growth hormone (GH) in Turner syndrome has an additive effect on adult height gain." | 4.91 | Novel approaches to short stature therapy. ( Oostdijk, W; Wit, JM, 2015) |
| "There has been no consensus regarding the efficacy and safety of oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS), the optimal age of starting this treatment, or the optimal dose." | 4.90 | Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. ( Bardsley, MZ; de Muinck Keizer-Schrama, SM; Donaldson, MD; Freriks, K; Gault, EJ; Menke, LA; Otten, BJ; Perry, RJ; Ross, JL; Sas, TC; Timmers, H; Wit, JM, 2014) |
| "Combined treatment with growth hormone and oxandrolone results in a significant increase of insulin secretion and increased insulin resistance." | 3.73 | [Carbohydrate metabolism in patients with Turner syndrome. The effect of therapy with growth hormone, oxandrolone and a combination of both]. ( Starzyk, J, 2005) |
| "To evaluate bone mass in patients with Turner syndrome by measuring metacarpal cortical thickness and bone diameter before and after treatment with oxandrolone, growth hormone (GH) and estrogens." | 3.73 | [Study of bone mass in Turner syndrome]. ( Cancer Gaspar, E; Ferrández Longás, A; Labarta Aizpún, JI; Mayayo Dehesa, E; Ruiz-Echarri Zelaya, M, 2005) |
| "In 18 girls with Turner syndrome, glucose tolerance was studied before treatment and after 6 and 24 months of growth-promoting treatment with recombinant human growth hormone (24 IU/m(2)/week; 8 mg/m(2)/week) and oxandrolone (0." | 3.70 | Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome. A longitudinal study. ( Joss, EE; Mullis, PE; Tönz, O; Zurbrügg, RP, 2000) |
| "To evaluate the effects of growth-promoting therapy on carbohydrate metabolism in girls with Turner syndrome, we determined glucose and insulin concentrations during oral glucose tolerance tests (OGTTs) at baseline and after 5 days, 2 months, and 12 months of treatment with growth hormone (GH), oxandrolone, or a combination of GH and oxandrolone, or after the same intervals with no therapy." | 3.67 | Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. ( Frane, JW; Hintz, RL; Johanson, AJ; Rosenfeld, RG; Sherman, B; Wilson, DM, 1988) |
| "Twenty-five patients with Turner Syndrome were treated with oxandrolone for six or more months." | 3.65 | Studies of anabolic steroids. VI. Effect of prolonged administration of oxandrolone on growth in children and adolescents with gonadal dysgenesis. ( Kelley, VC; Limbeck, GA; Moore, DC; Ruvalcaba, RH; Tattoni, DS, 1977) |
| "Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week)." | 2.76 | Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. ( Betts, P; Casey, S; Cole, TJ; Donaldson, MD; Dunger, DB; Gault, EJ; Hindmarsh, PC; Paterson, WF; Perry, RJ, 2011) |
| " The increase in BMI and waist circumference SDS was comparable between the dosage groups." | 2.75 | The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome. ( de Muinck Keizer-Schrama, SM; de Ridder, MA; Menke, LA; Otten, BJ; Sas, TC; Stijnen, T; Wit, JM; Zandwijken, GR, 2010) |
| "In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0." | 2.75 | Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. ( de Muinck Keizer-Schrama, SM; de Ridder, MA; Dejonckere, PH; Delemarre-van de Waal, HA; Gevers, EF; Hokken-Koelega, AC; Jansen, M; Menke, LA; Odink, RJ; Otten, BJ; Reeser, HM; Sas, TC; Stokvis-Brantsma, WH; van Buuren, S; van Trotsenburg, AS; Waelkens, JJ; Westerlaken, C; Wit, JM; Zandwijken, GR, 2010) |
| "The oxandrolone-treated group demonstrated improved performance after 2 yr, compared with the placebo group (P < 0." | 2.71 | Androgen-responsive aspects of cognition in girls with Turner syndrome. ( Bondy, C; Cutler, GB; Feuillan, P; Kushner, H; Roeltgen, D; Ross, JL; Stefanatos, GA, 2003) |
| " These data indicate that long term administration of rhGH has no significant impact on serum Lp(a) levels in girls with Turner's syndrome." | 2.69 | Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner's syndrome. ( Döpper, S; Gradehand, A; Kiencke, P; Querfeld, U; Wahn, F; Zeisel, HJ, 1999) |
| "The agonadal model, girls with Turner's syndrome (TS), has been used to determine the role of the hypothalamic pulse generator in the ontogeny of gonadotrophin secretion in man." | 2.69 | Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids. ( Brook, CG; Hindmarsh, PC; Massarano, AA; Nathwani, NC, 1998) |
| " Conventional GH doses are effective in increasing growth velocity in UTS, especially, when combined with Ox." | 2.68 | Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995) |
| "A total of 70 subjects with Turner's syndrome from 11 centres were enrolled in a study of somatrem." | 2.66 | Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner's syndrome. ( Hintz, RL; Johanson, AJ; Rosenfeld, RG; Sherman, B, 1987) |
| "Control patients with Turner's syndrome were matched by using the following criteria: difference in bone age being not greater than 0." | 2.65 | Oxandrolone in girls with Turner's syndrome. A pair-matched controlled study up to final height. ( Joss, E; Zuppinger, K, 1984) |
| "Turner's syndrome is the commonest sex chromosome abnormality in females, resulting from the absence of an X chromosome or the presence of a structurally abnormal X chromosome." | 2.42 | Growth and puberty in Turner's syndrome. ( Baroncelli, GI; Bertelloni, S; Fruzzetti, F; Saggese, G; Simi, P; Spinelli, C, 2003) |
| " Oestrogens are needed for secondary sex characteristics, but should be given in a low dosage and at approximately 12-13 years of age, in order not to compromise final height." | 2.38 | [Turner syndrome: a virtually certain indication for growth hormone treatment]. ( Rongen-Westerlaken, C; Wit, JM, 1992) |
| "Girls with Turner's Syndrome respond to growth hormone therapy." | 2.38 | Growth hormone therapy in Turner's syndrome. ( O'Shea, D; Powell, D, 1992) |
| "Children with Turner's syndrome will not have the same growth response as children who have classical growth hormone insufficiency." | 2.38 | Treatment of growth hormone insufficiency. ( Hindmarsh, PC, 1990) |
| "Turner syndrome is characterized by a great variability of clinical manifestations caused by a total or partial loss of X-chromosome." | 1.42 | Turner syndrome: From birth to adulthood. ( Grau Bolado, G; Martinez-Indart, L; Rica Echevarria, I; Ríos Orbañanos, I; Rodriguez Estevez, A; Vela Desojo, A, 2015) |
| "Mild virilization persists in only a small minority of patients." | 1.39 | Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome. ( de Muinck Keizer-Schrama, SM; Dejonckere, PH; den Heijer, M; Freriks, K; Gotthardt, M; Hermus, AR; Menke, LA; Netea-Maier, RT; Otten, BJ; Sas, TC; Timmers, HJ; Traas, MA; van Alfen-van der Velden, JA; Wit, JM; Zandwijken, GR, 2013) |
| "A number of typical features of Turner's syndrome were found, including a short webbed neck, cubitus valgus, shield chest, multiple pigmented nevi, lymphedema, epicanthus and micrognathia." | 1.35 | Hormonal therapy in a patient with a delayed diagnosis of Turner's syndrome. ( Gawlik, A; Malecka-Tendera, E, 2008) |
| "Patients with Turner syndrome have higher blood pressure measurements compared to published population standards, as evidenced by the shift to the right of both the systolic and diastolic BP SDS." | 1.31 | Blood pressure and Turner syndrome. ( Brook, CG; Hindmarsh, PC; Nathwani, NC; Unwin, R, 2000) |
| "We have studied the course over age of fasting insulin, sex hormone-binding globulin (SHBG), and insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) in untreated children with Turner's syndrome (TS) and measured the course of these parameters during therapy with GH alone and in combination with oxandrolone." | 1.29 | Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T, 1996) |
| " The dosage were: GH, 0." | 1.29 | Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. ( Albertsson-Wikland, K; Alm, J; Aman, J; Aronson, S; Gustafsson, J; Hagenäs, L; Häger, A; Ivarsson, SA; Karlberg, J; Kriström, B; Marcus, C; Moell, C; Nilsson, KO; Ritzen, M; Tuvemo, T; Wattsgård, C; Westgren, U; Westphal, O, 1996) |
| " Subsequently, all patients received GH 18 IU/m2/week in combination with oxandrolone (Ox) (0." | 1.29 | Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T, 1996) |
| "Patients with Turner's syndrome who had lower basal IGF-I levels had significantly higher responses of IGF-I, free fatty acids and hydroxyproline (P less than 0." | 1.28 | Growth hormone treatment in Turner's syndrome: short and long-term effects on metabolic parameters. ( Frisch, H; Haeusler, G, 1992) |
| "Forty-eight girls with Turner's syndrome were assigned to one of three treatments; recombinant human growth hormone (rhGH) alone, rhGH plus oxandrolone, and rhGH plus ethinyloestradiol." | 1.28 | Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group. ( Anton, R; Arnal, JM; Buñuel, C; Ferrández, A; García, C; Lasarte, JJ; Mayayo, E; Puyuelo, P, 1989) |
| "To evaluate the relationship between the secretion of gonadotropins and adrenal androgens, patients with gonadal agenesis were evaluated by (a) administering human luteinizing hormone (hLH) for 5 days with or without estrogen pretreatment to agonadal patients who had prepubertal LH levels; (b) correlating circulating gonadotropin levels with adrenal androgens in 45 patients; and (c) comparing adrenal androgens with gonadotropins after long-term administration of estrogen or androgens." | 1.25 | Lack of correlation between gonadotropin and adrenal androgen levels in agonadal children. ( Blizzard, RM; Kowarski, A; Lee, PA; Migeon, CJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (25.74) | 18.7374 |
| 1990's | 35 (34.65) | 18.2507 |
| 2000's | 19 (18.81) | 29.6817 |
| 2010's | 20 (19.80) | 24.3611 |
| 2020's | 1 (0.99) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, S | 1 |
| Alkofide, H | 1 |
| Adi, YA | 1 |
| Amer, YS | 1 |
| AlFaleh, K | 1 |
| Gault, EJ | 5 |
| Cole, TJ | 3 |
| Casey, S | 2 |
| Hindmarsh, PC | 7 |
| Betts, P | 2 |
| Dunger, DB | 3 |
| Donaldson, MDC | 1 |
| Perry, RJ | 3 |
| Paterson, WF | 2 |
| Donaldson, MD | 5 |
| Sas, TC | 10 |
| Bardsley, MZ | 1 |
| Menke, LA | 10 |
| Freriks, K | 4 |
| Otten, BJ | 9 |
| de Muinck Keizer-Schrama, SM | 9 |
| Timmers, H | 1 |
| Wit, JM | 12 |
| Ross, JL | 4 |
| Verver, EJ | 1 |
| Huygen, PL | 1 |
| Pennings, RJ | 1 |
| Smeets, DF | 2 |
| Hermus, AR | 3 |
| van Alfen-van der Velden, JA | 2 |
| Topsakal, V | 1 |
| Admiraal, RJ | 1 |
| Timmers, HJ | 3 |
| Kunst, HP | 1 |
| Verhaak, CM | 1 |
| Netea-Maier, RT | 2 |
| Kessels, RP | 1 |
| Oostdijk, W | 1 |
| Ríos Orbañanos, I | 1 |
| Vela Desojo, A | 1 |
| Martinez-Indart, L | 1 |
| Grau Bolado, G | 1 |
| Rodriguez Estevez, A | 1 |
| Rica Echevarria, I | 1 |
| Mazzocco, MM | 1 |
| Kushner, H | 3 |
| Kowal, K | 2 |
| Cutler, GB | 3 |
| Roeltgen, D | 2 |
| Visser, M | 1 |
| Kreukels, BP | 1 |
| Stijnen, T | 3 |
| Zandwijken, GR | 6 |
| Cohen-Kettenis, PT | 1 |
| de Ridder, MA | 3 |
| Odink, RJ | 1 |
| Jansen, M | 1 |
| Delemarre-van de Waal, HA | 1 |
| Stokvis-Brantsma, WH | 1 |
| Waelkens, JJ | 1 |
| Westerlaken, C | 1 |
| Reeser, HM | 1 |
| van Trotsenburg, AS | 1 |
| Gevers, EF | 1 |
| van Buuren, S | 1 |
| Dejonckere, PH | 3 |
| Hokken-Koelega, AC | 1 |
| Andrade, AC | 1 |
| Baron, J | 1 |
| Manolagas, SC | 1 |
| Shaw, NJ | 1 |
| Rappold, GA | 1 |
| Sävendahl, L | 2 |
| Ben-Shlomo, Y | 1 |
| Zeger, MP | 1 |
| Shah, K | 1 |
| van Koningsbrugge, SH | 1 |
| Boersma, B | 1 |
| Fonteles, AV | 1 |
| Dondoni, RS | 1 |
| Boguszewski, MC | 1 |
| Nesi-França, S | 1 |
| Marques-Pereira, R | 1 |
| Sandrini Neto, R | 1 |
| Lacerda Filho, Ld | 1 |
| Davenport, ML | 1 |
| Traas, MA | 1 |
| den Heijer, M | 1 |
| Gotthardt, M | 1 |
| Stefanatos, GA | 1 |
| Feuillan, P | 1 |
| Bondy, C | 1 |
| Ságodi, L | 1 |
| Sólyom, E | 1 |
| Bertelloni, S | 1 |
| Baroncelli, GI | 1 |
| Fruzzetti, F | 1 |
| Spinelli, C | 1 |
| Simi, P | 1 |
| Saggese, G | 1 |
| Parvin, M | 1 |
| Roche, E | 1 |
| Costigan, C | 1 |
| Hoey, HM | 1 |
| Gracia Bouthelier, R | 1 |
| Oliver Iguacel, A | 1 |
| Gonzalez Casado, I | 1 |
| Alcalde de Alvaré, A | 1 |
| Cancer Gaspar, E | 1 |
| Ruiz-Echarri Zelaya, M | 1 |
| Labarta Aizpún, JI | 1 |
| Mayayo Dehesa, E | 1 |
| Ferrández Longás, A | 1 |
| Starzyk, J | 1 |
| Laurencikas, E | 1 |
| Söderman, E | 1 |
| Davenport, M | 1 |
| Jorulf, H | 1 |
| Cutter, WJ | 1 |
| Daly, EM | 1 |
| Robertson, DM | 1 |
| Chitnis, XA | 1 |
| van Amelsvoort, TA | 1 |
| Simmons, A | 1 |
| Ng, VW | 1 |
| Williams, BS | 1 |
| Shaw, P | 1 |
| Conway, GS | 1 |
| Skuse, DH | 1 |
| Collier, DA | 1 |
| Craig, M | 1 |
| Murphy, DG | 1 |
| Gawlik, A | 1 |
| Malecka-Tendera, E | 1 |
| Ramos, AV | 1 |
| Silva, IN | 1 |
| Goulart, EM | 1 |
| Schönberger, W | 1 |
| Benes, P | 1 |
| Morsches, B | 1 |
| Zabel, B | 1 |
| Scheidt, E | 1 |
| Joss, E | 1 |
| Zuppinger, K | 1 |
| Vuković, D | 1 |
| Rudman, D | 1 |
| Goldsmith, M | 1 |
| Kutner, M | 1 |
| Blackston, D | 1 |
| Root, AW | 1 |
| Stahnke, N | 3 |
| Willig, RP | 1 |
| Haeusler, G | 4 |
| Frisch, H | 5 |
| Schmitt, K | 4 |
| Blümel, P | 5 |
| Plöchl, E | 4 |
| Zachmann, M | 1 |
| Waldhör, T | 4 |
| Frasier, SD | 1 |
| Lippe, BM | 3 |
| Ranke, MB | 5 |
| Grauer, ML | 1 |
| Andersson-Wallgren, G | 1 |
| Albertsson-Wikland, K | 3 |
| Saenger, P | 2 |
| Lu, PW | 1 |
| Cowell, CT | 1 |
| Rochiccioli, P | 2 |
| Battin, J | 1 |
| Bertrand, AM | 1 |
| Bost, M | 1 |
| Cabrol, S | 1 |
| le Bouc, Y | 1 |
| Chaussain, JL | 1 |
| Chatelain, P | 2 |
| Colle, M | 1 |
| Czernichow, P | 1 |
| Nilsson, KO | 2 |
| Alm, J | 1 |
| Aronson, S | 1 |
| Gustafsson, J | 1 |
| Hagenäs, L | 1 |
| Häger, A | 1 |
| Ivarsson, SA | 1 |
| Karlberg, J | 1 |
| Kriström, B | 1 |
| Marcus, C | 1 |
| Moell, C | 1 |
| Ritzen, M | 1 |
| Tuvemo, T | 1 |
| Wattsgård, C | 1 |
| Westgren, U | 1 |
| Westphal, O | 1 |
| Aman, J | 1 |
| Häusler, G | 1 |
| Joss, EE | 3 |
| Mullis, PE | 2 |
| Werder, EA | 1 |
| Partsch, CJ | 1 |
| Sippell, WG | 1 |
| Bareille, P | 1 |
| Massarano, AA | 3 |
| Stanhope, R | 3 |
| Rosenfeld, RG | 11 |
| Attie, KM | 2 |
| Frane, J | 5 |
| Brasel, JA | 4 |
| Burstein, S | 4 |
| Cara, JF | 2 |
| Chernausek, S | 3 |
| Gotlin, RW | 4 |
| Kuntze, J | 3 |
| Mahoney, CP | 1 |
| Moore, WV | 1 |
| Johanson, AJ | 6 |
| Nicholls, D | 1 |
| Nathwani, NC | 3 |
| Brook, CG | 4 |
| Querfeld, U | 1 |
| Döpper, S | 1 |
| Gradehand, A | 1 |
| Kiencke, P | 1 |
| Wahn, F | 1 |
| Zeisel, HJ | 1 |
| Cacciari, E | 1 |
| Mazzanti, L | 1 |
| Unwin, R | 2 |
| Zurbrügg, RP | 1 |
| Tönz, O | 1 |
| Lindberg, A | 1 |
| Wilton, P | 1 |
| Cutfield, W | 1 |
| Price, DA | 1 |
| Bramswig, JH | 1 |
| Keller, E | 2 |
| Landy, H | 1 |
| Lee, PA | 2 |
| Kowarski, A | 1 |
| Migeon, CJ | 2 |
| Blizzard, RM | 1 |
| Moore, DC | 1 |
| Tattoni, DS | 1 |
| Ruvalcaba, RH | 1 |
| Limbeck, GA | 1 |
| Kelley, VC | 1 |
| Urban, MD | 1 |
| Dorst, JP | 1 |
| Plotnick, LP | 1 |
| Crawford, JD | 1 |
| Rosenfield, RL | 1 |
| Lucky, AW | 1 |
| Pierson, M | 1 |
| Leheup, B | 1 |
| Ferrández, A | 2 |
| Mayayo, E | 2 |
| Sanjuan, P | 1 |
| Bello, E | 1 |
| Labarta, JI | 1 |
| Rongen-Westerlaken, C | 1 |
| Stubbe, P | 1 |
| Tauber, MT | 1 |
| O'Shea, D | 1 |
| Powell, D | 1 |
| Job, JC | 1 |
| Landier, F | 1 |
| Cherubini, V | 1 |
| Cardinale, G | 1 |
| Panfoli, C | 1 |
| Pecora, R | 1 |
| Lorenzetti, L | 1 |
| Bartolotta, E | 1 |
| Crock, P | 1 |
| Werther, GA | 1 |
| Wettenhall, HN | 1 |
| Stögmann, W | 1 |
| Pringle, PJ | 1 |
| Teale, JD | 1 |
| Preece, MA | 1 |
| Arnal, JM | 1 |
| García, C | 1 |
| Buñuel, C | 1 |
| Lasarte, JJ | 1 |
| Anton, R | 1 |
| Puyuelo, P | 1 |
| Lippe, B | 1 |
| Hintz, RL | 5 |
| Sherman, B | 4 |
| Wilson, DM | 2 |
| Frane, JW | 1 |
| Compton, P | 1 |
| Chernausek, SD | 1 |
| Clabots, T | 1 |
| Bryan, GT | 1 |
| Rosenbloom, AL | 1 |
| Frias, JL | 1 |
| Rosenblum, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome[NCT00029159] | Phase 3 | 200 participants (Actual) | Interventional | 1992-11-30 | Completed | ||
| Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters[NCT00732693] | Phase 4 | 42 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Trial of the Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome[NCT00001221] | Phase 2 | 160 participants | Interventional | 1987-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for oxandrolone and Turner Syndrome
| Article | Year |
|---|---|
Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome.
Topics: Adolescent; Androgens; Body Height; Female; Human Growth Hormone; Humans; Oxandrolone; Randomized Co | 2019 |
Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use.
Topics: Adolescent; Adult; Age Factors; Androgens; Child; Child, Preschool; Double-Blind Method; Female; Hum | 2014 |
Novel approaches to short stature therapy.
Topics: Achondroplasia; Androgens; Aromatase Inhibitors; Dwarfism, Pituitary; Gonadotropin-Releasing Hormone | 2015 |
Hormones and genes of importance in bone physiology and their influence on bone mineralization and growth in Turner syndrome.
Topics: Adolescent; Body Height; Bone Density; Bone Development; Bone Diseases, Metabolic; Calcification, Ph | 2010 |
Growth and puberty in Turner's syndrome.
Topics: Anabolic Agents; Estrogen Replacement Therapy; Female; Growth; Growth Hormone; Humans; Oxandrolone; | 2003 |
Management of Turner's syndrome.
Topics: Androgens; Body Height; Estrogens; Female; Fertility; Growth Hormone; Humans; Oxandrolone; Pregnancy | 2004 |
Optimization of treatment in Turner's syndrome.
Topics: Growth Hormone; Humans; Oxandrolone; Recombinant Proteins; Treatment Outcome; Turner Syndrome | 2004 |
Clinical review 48: The current status of diagnosis and therapeutic intervention in Turner's syndrome.
Topics: Adolescent; Adult; Aortic Coarctation; Calcium, Dietary; Carbohydrate Metabolism, Inborn Errors; Chi | 1993 |
Growth hormone therapy in Turner syndrome. Analysis of long-term results.
Topics: Anabolic Agents; Body Height; Drug Combinations; Growth; Growth Hormone; Humans; Oxandrolone; Turner | 1995 |
Long-term results of growth hormone therapy in Turner syndrome.
Topics: Adolescent; Body Height; Child; Estrogens; Female; Human Growth Hormone; Humans; Oxandrolone; Turner | 2001 |
[Turner's syndrome is not what it was in the past].
Topics: Adolescent; Adult; Body Height; Child; Child, Preschool; Developmental Disabilities; Drug Therapy, C | 1992 |
Current concepts in the treatment of Turner syndrome with special reference to the treatment of short stature.
Topics: Age Factors; Body Height; Child; Child, Preschool; Developmental Disabilities; Ethinyl Estradiol; Fe | 1992 |
[Turner syndrome: a virtually certain indication for growth hormone treatment].
Topics: Age Determination by Skeleton; Body Height; Child; Dose-Response Relationship, Drug; Drug Therapy, C | 1992 |
[Turner's syndrome: a revolution].
Topics: Adolescent; Adult; Body Height; Child; Child, Preschool; Drug Therapy, Combination; Estrogens; Femal | 1992 |
Growth hormone therapy in Turner's syndrome.
Topics: Body Height; Drug Therapy, Combination; Female; Growth Hormone; Humans; Oxandrolone; Turner Syndrome | 1992 |
Treatment of growth hormone insufficiency.
Topics: Child; Child, Preschool; Chorionic Gonadotropin; Growth Disorders; Humans; Infant; Noonan Syndrome; | 1990 |
What is the value of growth hormone treatment in short children with specified syndrome? Turner's syndrome, osteochondrodysplasias, Prader-Willi syndrome, Noonan syndrome.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Est | 1989 |
[The current treatment concept of Turner syndrome].
Topics: Adolescent; Body Height; Child; Drug Therapy, Combination; Estradiol; Ethinyl Estradiol; Female; Gro | 1989 |
Anabolic steroids in girls with Turner's syndrome.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Child; Child, Preschool; Female; Humans; Oxa | 1988 |
Treatment of short stature and delayed adolescence.
Topics: Adolescent; Body Height; Child; Female; Growth Disorders; Growth Hormone; Humans; Male; Oxandrolone; | 1987 |
38 trials available for oxandrolone and Turner Syndrome
| Article | Year |
|---|---|
Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial.
Topics: Anabolic Agents; Body Height; Child; Drug Administration Schedule; Female; Humans; Male; Oxandrolone | 2021 |
Effect of oxandrolone and timing of oral ethinylestradiol initiation on pubertal progression, height velocity and bone maturation in the UK Turner study.
Topics: Administration, Oral; Adolescent; Androgens; Estrogens; Ethinyl Estradiol; Female; Humans; Oxandrolo | 2014 |
Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment.
Topics: Adolescent; Adult; Anabolic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-U | 2014 |
Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life and social-emotional functioning in young adults with Turner syndrome.
Topics: Adolescent; Adult; Androgens; Cognition; Depression; Emotional Intelligence; Emotions; Estrogens; Fe | 2015 |
Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome.
Topics: Adolescent; Androgens; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 2009 |
The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome.
Topics: Adolescent; Affect; Aggression; Androgens; Child; Child, Preschool; Double-Blind Method; Drug Therap | 2010 |
Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
Topics: Adolescent; Age Factors; Androgens; Blood Pressure; Body Height; Chi-Square Distribution; Child; Chi | 2010 |
The effect of oxandrolone on body proportions and body composition in growth hormone-treated girls with Turner syndrome.
Topics: Adolescent; Algorithms; Androgens; Body Composition; Body Size; Child; Child, Preschool; Double-Blin | 2010 |
Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome.
Topics: Adolescent; Adolescent Development; Androgens; Body Height; Bone Density; Child; Child Development; | 2011 |
Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome.
Topics: Carbohydrate Metabolism; Child; Estrogens; Fasting; Female; Glucose; Glycated Hemoglobin; Human Grow | 2011 |
The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.
Topics: Adolescent; Anabolic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Estrogens; F | 2011 |
Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial.
Topics: Adolescent; Anabolic Agents; Body Height; Child; Double-Blind Method; Female; Growth Disorders; Huma | 2011 |
[Final height (FH) in Turner syndrome (TS): experience of 76 cases followed at the Pediatric Endocrinology Unit, Hospital de Clinicas, Federal University of Paraná].
Topics: Adolescent; Age Determination by Skeleton; Androgens; Body Height; Child; Child, Preschool; Estrogen | 2011 |
Androgen-responsive aspects of cognition in girls with Turner syndrome.
Topics: Anabolic Agents; Child; Cognition; Female; Humans; Oxandrolone; Safety; Turner Syndrome | 2003 |
[Optimizing estrogen treatment in Turner syndrome].
Topics: Adolescent; Anabolic Agents; Body Height; Child; Estrogens; Female; Growth Hormone; Humans; Menarche | 2003 |
Oxandrolone in girls with Turner's syndrome. A pair-matched controlled study up to final height.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Child; Clinical Trials as Topic; Ethinyl Est | 1984 |
Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Child; Drug Administration Schedule; Drug Th | 1980 |
Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.
Topics: Age Determination by Skeleton; Body Height; Body Weight; Carrier Proteins; Child; Drug Therapy, Comb | 1995 |
Final height in Turner syndrome patients treated with growth hormone.
Topics: Age Determination by Skeleton; Anabolic Agents; Body Height; Child; Chromosome Aberrations; Chromoso | 1995 |
The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich-Turner syndrome.
Topics: Adolescent; Adult; Anabolic Agents; Child; Drug Therapy, Combination; Female; Growth Hormone; Humans | 1997 |
Growth promotion and Turner-specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome?
Topics: Age Determination by Skeleton; Age Factors; Anabolic Agents; Body Height; Bone and Bones; Child; Dru | 1997 |
Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone.
Topics: Adolescent; Anabolic Agents; Body Height; Child; Drug Therapy, Combination; Estrogens; Female; Follo | 1997 |
Growth hormone therapy of Turner's syndrome: beneficial effect on adult height.
Topics: Anabolic Agents; Body Height; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth Hor | 1998 |
Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids.
Topics: Anabolic Agents; Biomarkers; Case-Control Studies; Child; Child, Preschool; Estradiol Congeners; Eth | 1998 |
Long-term treatment with growth hormone has no persisting effect on lipoprotein(a) in patients with Turner's syndrome.
Topics: Adolescent; Apolipoproteins A; Child; Drug Combinations; Female; Human Growth Hormone; Humans; Lipop | 1999 |
Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome.
Topics: Adolescent; Body Height; Child; Ethinyl Estradiol; Female; Human Growth Hormone; Humans; Karyotyping | 1999 |
Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study.
Topics: Anabolic Agents; Body Height; Child; Cohort Studies; Databases as Topic; Female; Growth; Human Growt | 2000 |
Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age.
Topics: Adolescent; Age Determination by Skeleton; Aging; Anabolic Agents; Body Height; Child; Cholesterol; | 2002 |
Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.
Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Drug Therapy, Combination; Fema | 1992 |
Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome.
Topics: Aging; Body Height; Body Weight; Bone Development; Child; Female; Growth Disorders; Growth Hormone; | 1992 |
Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome.
Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Drug Combinations; Female; Grow | 1992 |
Three-year results of treatment with growth hormone, alone or associated with oxandrolone, in girls with Turner syndrome. The Kabi Collaborative Study Group.
Topics: Adolescent; Body Height; Child; Female; Growth Hormone; Humans; Oxandrolone; Turner Syndrome | 1991 |
Non-conventional growth hormone therapy in Turner syndrome: the United States experience.
Topics: Body Height; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth; Growth Hormone; Hum | 1990 |
Oxandrolone increases final height in Turner syndrome.
Topics: Adolescent; Age Factors; Body Height; Child; Drug Evaluation; Ethinyl Estradiol; Female; Humans; Oxa | 1990 |
Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results.
Topics: Body Height; Child; Child, Preschool; Drug Combinations; Female; Growth; Growth Hormone; Humans; Met | 1989 |
Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner's syndrome.
Topics: Age Determination by Skeleton; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Comb | 1987 |
Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome.
Topics: Body Height; Child; Child, Preschool; Drug Therapy, Combination; Female; Growth; Growth Hormone; Hor | 1988 |
Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial.
Topics: Adolescent; Adult; Age Determination by Skeleton; Body Height; Child; Child, Preschool; Clinical Tri | 1986 |
43 other studies available for oxandrolone and Turner Syndrome
| Article | Year |
|---|---|
Turner syndrome: From birth to adulthood.
Topics: Adolescent; Adult; Cardiovascular Diseases; Child; Child, Preschool; Delayed Diagnosis; Dwarfism; Fe | 2015 |
SITAR--a useful instrument for growth curve analysis.
Topics: Adolescent; Age Distribution; Body Height; Child; Cohort Studies; Female; Growth Charts; Humans; Ins | 2010 |
Comments on 'Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome' by Zeger et al., pp. 39-47, this issue.
Topics: Adolescent; Adolescent Development; Androgens; Body Height; Drug Monitoring; Drug Therapy, Combinati | 2011 |
Growth hormone therapy in Turner syndrome.
Topics: Anabolic Agents; Body Height; Child; Drug Therapy, Combination; Estrogens; Female; Growth Hormone; H | 2012 |
Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome.
Topics: Adult; Body Height; Breast; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; | 2013 |
Treatment outcome in Turner syndrome.
Topics: Adolescent; Body Height; Body Weight; Child; Dose-Response Relationship, Drug; Drug Administration S | 2004 |
[Study of bone mass in Turner syndrome].
Topics: Adolescent; Anabolic Agents; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Estrog | 2005 |
[Carbohydrate metabolism in patients with Turner syndrome. The effect of therapy with growth hormone, oxandrolone and a combination of both].
Topics: Adolescent; Anabolic Agents; Blood Glucose; Carbohydrate Metabolism; Child; Child, Preschool; Diabet | 2005 |
Metacarpophalangeal pattern profile analysis as a tool for early diagnosis of Turner syndrome.
Topics: Adolescent; Adult; Anabolic Agents; Child; Child, Preschool; Cohort Studies; Discriminant Analysis; | 2005 |
Influence of X chromosome and hormones on human brain development: a magnetic resonance imaging and proton magnetic resonance spectroscopy study of Turner syndrome.
Topics: Adult; Aspartic Acid; Brain; Choline; Chromosomes, Human, X; Female; Gonadal Steroid Hormones; Human | 2006 |
Hormonal therapy in a patient with a delayed diagnosis of Turner's syndrome.
Topics: Adolescent; Body Height; Estrogens; Female; Human Growth Hormone; Humans; Oxandrolone; Turner Syndro | 2008 |
Turner syndrome: searching for better outcomes.
Topics: Anabolic Agents; Body Height; Child; Cohort Studies; Estrogen Replacement Therapy; Female; Follow-Up | 2008 |
[Improvement in the longitudinal growth in Ullrich-Turner syndrome with oxandrolone. Function of urinary excretion of steroid hormones].
Topics: Adolescent; Adrenal Cortex Hormones; Age Determination by Skeleton; Androsterone; Body Height; Child | 1982 |
[Therapy of Turner's syndrome with oxandrolone].
Topics: Adolescent; Child; Female; Growth Disorders; Humans; Male; Oxandrolone; Turner Syndrome | 1983 |
Use of oxandrolone in Turner syndrome.
Topics: Adult; Body Height; Child; Estrogens; Female; Humans; Oxandrolone; Turner Syndrome | 1980 |
Treatment of short stature in Turner syndrome.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Child; Female; Growth; Humans; Oxandrolone; | 1980 |
Short stature.
Topics: Adolescent; Child; Cushing Syndrome; Female; Growth Disorders; Growth Hormone; Humans; Hypothyroidis | 1994 |
Adult height in Turner syndrome: results of a multinational survey 1993.
Topics: Adolescent; Adult; Body Height; Estrogens; Europe; Female; Health Surveys; Humans; Japan; Middle Age | 1994 |
Change in speaking fundamental frequency in hormone-treated patients with Turner's syndrome--a longitudinal study of four cases.
Topics: Adolescent; Child; Drug Therapy, Combination; Ethinyl Estradiol; Female; Growth Hormone; Humans; Lon | 1994 |
Combined therapy with growth hormone and oxandrolone in adolescent girls with Turner syndrome.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Bone Development; Child; Drug Therapy, Combi | 1993 |
Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
Topics: Adolescent; Aging; Child; Child, Preschool; Cross-Sectional Studies; Female; Growth Hormone; Humans; | 1996 |
Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
Topics: Adolescent; Age Determination by Skeleton; Anabolic Agents; Body Height; Child; Ethinyl Estradiol; F | 1996 |
Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.
Topics: Age Determination by Skeleton; Anabolic Agents; Body Height; Child; Ethinyl Estradiol; Female; Growt | 1996 |
Turner's syndrome, anorexia nervosa, and anabolic steroids.
Topics: Anabolic Agents; Anorexia Nervosa; Child; Drug Therapy, Combination; Estrogens; Female; Humans; Oxan | 1998 |
Turner syndrome.
Topics: Adolescent; Age Factors; Anabolic Agents; Body Height; Child; Drug Therapy, Combination; Female; Hum | 1999 |
Blood pressure and Turner syndrome.
Topics: Adolescent; Adult; Anabolic Agents; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Chi | 2000 |
The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome.
Topics: Adolescent; Adult; Anabolic Agents; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Chi | 2000 |
Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome. A longitudinal study.
Topics: Adolescent; Adult; Anabolic Agents; Blood Glucose; Child; Diabetes Mellitus; Drug Therapy, Combinati | 2000 |
Lack of correlation between gonadotropin and adrenal androgen levels in agonadal children.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Androgens; Dehydroepiandrosterone; Estrogens, Conjugated ( | 1975 |
Studies of anabolic steroids. VI. Effect of prolonged administration of oxandrolone on growth in children and adolescents with gonadal dysgenesis.
Topics: Age Determination by Skeleton; Body Height; Child; Female; Gonads; Growth; Humans; Oxandrolone; Turn | 1977 |
Oxandrolone therapy in patients with Turner syndrome.
Topics: Body Height; Bone and Bones; Drug Administration Schedule; Drug Therapy, Combination; Fluoxymesteron | 1979 |
Management of children with Turner's syndrome.
Topics: Adolescent; Child; Estrogens; Female; Growth Disorders; Heart Defects, Congenital; Humans; Keloid; O | 1979 |
Oxandrolone therapy for children with Turner syndrome.
Topics: Body Height; Bone Development; Child; Female; Humans; Oxandrolone; Turner Syndrome | 1977 |
[Treatment of Turner syndrome].
Topics: Adolescent; Body Height; Child; Estrogens; Female; Growth; Growth Hormone; Humans; Oxandrolone; Turn | 1992 |
Growth hormone treatment in Turner's syndrome: short and long-term effects on metabolic parameters.
Topics: Adolescent; Bone Development; Child; Drug Therapy, Combination; Ethinyl Estradiol; Fatty Acids, None | 1992 |
[The effects of treatment with growth hormone alone or in combination with oxandrolone in a group of Turner's syndrome children. A preliminary study].
Topics: Adolescent; Body Height; Child; Drug Evaluation; Drug Therapy, Combination; Female; Growth Hormone; | 1991 |
Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol.
Topics: Body Height; Child; Child, Preschool; Ethinyl Estradiol; Female; Growth Hormone; Humans; Insulin-Lik | 1989 |
Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group.
Topics: Adolescent; Bone Development; Child; Child, Preschool; Drug Therapy, Combination; Ethinyl Estradiol; | 1989 |
Treatment of Turner's syndrome with recombinant human growth hormone (somatrem).
Topics: Body Height; Child; Child, Preschool; Drug Therapy, Combination; Female; Glucose; Growth Hormone; Hu | 1988 |
Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both.
Topics: Blood Glucose; Carbohydrate Metabolism; Child; Child, Preschool; Drug Therapy, Combination; Female; | 1988 |
Normal and abnormal sexual maturation.
Topics: Adolescent; Adrenal Gland Diseases; Age Determination by Skeleton; Bone Development; Breast; Central | 1974 |
Oxandrolone for growth promotion in Turner syndrome.
Topics: Adolescent; Body Height; Body Weight; Bone and Bones; Child; Female; Growth; Humans; Osteogenesis; O | 1973 |
Letter: Oxandrolone for growth stimulation.
Topics: Body Height; Female; Growth Disorders; Humans; Male; Oxandrolone; Turner Syndrome | 1974 |